Innate endogenous adjuvants prime to desirable immune responses via mucosal routes
- PMID: 25503634
- PMCID: PMC4348248
- DOI: 10.1007/s13238-014-0125-1
Innate endogenous adjuvants prime to desirable immune responses via mucosal routes
Abstract
Vaccination is an effective strategy to prevent infectious or immune related diseases, which has made remarkable contribution in human history. Recently increasing attentions have been paid to mucosal vaccination due to its multiple advantages over conventional ways. Subunit or peptide antigens are more reasonable immunogens for mucosal vaccination than live or attenuated pathogens, however adjuvants are required to augment the immune responses. Many mucosal adjuvants have been developed to prime desirable immune responses to different etiologies. Compared with pathogen derived adjuvants, innate endogenous molecules incorporated into mucosal vaccines demonstrate prominent adjuvanticity and safety. Nowadays, cytokines are broadly used as mucosal adjuvants for participation of signal transduction of immune responses, activation of innate immunity and polarization of adaptive immunity. Desired immune responses are promptly and efficaciously primed on basis of specific interactions between cytokines and corresponding receptors. In addition, some other innate molecules are also identified as potent mucosal adjuvants. This review focuses on innate endogenous mucosal adjuvants, hoping to shed light on the development of mucosal vaccines.
Similar articles
-
Modes of Action for Mucosal Vaccine Adjuvants.Viral Immunol. 2017 Jul/Aug;30(6):463-470. doi: 10.1089/vim.2017.0026. Epub 2017 Apr 24. Viral Immunol. 2017. PMID: 28436755 Free PMC article. Review.
-
Generation of improved mucosal vaccines by induction of innate immunity.Cell Mol Life Sci. 2005 Dec;62(23):2750-70. doi: 10.1007/s00018-005-5290-1. Cell Mol Life Sci. 2005. PMID: 16237500 Free PMC article. Review.
-
Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines.Immunol Cell Biol. 2004 Dec;82(6):617-27. doi: 10.1111/j.1440-1711.2004.01288.x. Immunol Cell Biol. 2004. PMID: 15550120 Review.
-
Mucosal delivery of vaccine antigens and its advantages in pediatrics.Adv Drug Deliv Rev. 2006 Apr 20;58(1):52-67. doi: 10.1016/j.addr.2006.01.002. Epub 2006 Mar 3. Adv Drug Deliv Rev. 2006. PMID: 16516335 Review.
-
New insights in mucosal vaccine development.Vaccine. 2012 Jan 5;30(2):142-54. doi: 10.1016/j.vaccine.2011.11.003. Epub 2011 Nov 12. Vaccine. 2012. PMID: 22085556 Review.
Cited by
-
Recent advances in respiratory immunization: A focus on COVID-19 vaccines.J Control Release. 2023 Mar;355:655-674. doi: 10.1016/j.jconrel.2023.02.011. Epub 2023 Feb 17. J Control Release. 2023. PMID: 36787821 Free PMC article. Review.
-
Development of Nasal Vaccines and the Associated Challenges.Pharmaceutics. 2022 Sep 20;14(10):1983. doi: 10.3390/pharmaceutics14101983. Pharmaceutics. 2022. PMID: 36297419 Free PMC article. Review.
-
Innovative Mucosal Vaccine Formulations Against Influenza A Virus Infections.Front Immunol. 2019 Jul 17;10:1605. doi: 10.3389/fimmu.2019.01605. eCollection 2019. Front Immunol. 2019. PMID: 31379823 Free PMC article. Review.
-
Intranasal COVID-19 vaccines: From bench to bed.EBioMedicine. 2022 Feb;76:103841. doi: 10.1016/j.ebiom.2022.103841. Epub 2022 Jan 24. EBioMedicine. 2022. PMID: 35085851 Free PMC article. Review.
-
COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges.Hum Vaccin Immunother. 2022 Nov 30;18(5):2045853. doi: 10.1080/21645515.2022.2045853. Epub 2022 Mar 8. Hum Vaccin Immunother. 2022. PMID: 35258416 Free PMC article. Review.
References
-
- Abraham E, Shah S. Intranasal immunization with liposomes containing IL-2 enhances bacterial polysaccharide antigen-specific pulmonary secretory antibody-response. J Immunol. 1992;149:3719–3726. - PubMed
-
- Arulanandam BP, Lynch JM, Briles DE, Hollingshead S, Metzger DW. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun. 2001;69:6718–6724. doi: 10.1128/IAI.69.11.6718-6724.2001. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical